Equities
Health CareHealth Care Equipment & Services
  • Price (EUR)18.01
  • Today's Change0.08 / 0.45%
  • Shares traded25.94k
  • 1 Year change30.13%
  • Beta1.4681
Data delayed at least 15 minutes, as of Jun 25 2019 10:46 BST.
More ▼

Profile data is unavailable for this security.

About the company

Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. It operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.

  • Revenue in EUR (TTM)471.68m
  • Net income in EUR42.86m
  • Incorporated2007
  • Employees2.49k
  • Location
    Fagron NVVenecoweg 20ANAZARETH 9810BelgiumBEL
  • Phone+32 80012880
  • Fax+32 92162491
  • Websitehttps://fagron.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
FAGR:BRU since
announced
Transaction
value
Central De Drogas SA De CVAnnounced13 May 201913 May 2019Announced5.44%24.22m
Data delayed at least 15 minutes, as of Jun 25 2019 10:46 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CellaVision AB36.98m9.17m674.29m124.0072.7822.3867.1818.054.074.0716.4013.231.073.647.433,342,667.0026.5424.0031.6830.0074.1971.8324.8021.684.042,022.390.087155.2017.9415.1927.2036.1914.1924.57
Biotage AB89.90m16.10m708.33m413.0042.418.7833.397.642.632.6314.6712.690.8542.814.922,347,820.0015.2915.1218.2018.3461.3058.6017.9115.671.82--0.171474.2521.7515.4220.8132.282.6720.11
Stratec SE187.82m11.11m732.52m1.23k64.474.6822.803.800.92450.746415.6212.720.69683.115.01152,947.904.129.764.7111.9028.4732.135.9211.361.7616.300.335746.04-9.477.98-58.22-6.4214.016.45
Draegerwerk AG & Co KGaA2.70bn43.96m779.54m14.60k20.280.84045.270.28812.482.48152.0959.731.133.214.56187,587.602.253.083.204.5342.8444.801.992.771.298.270.15113.760.88461.79-65.10-25.85-6.87-25.54
Arjo AB (publ)793.93m32.71m1.01bn6.14k32.901.969.551.271.271.2730.8321.310.6213.714.761,362,044.002.56--3.83--44.58--4.12--0.58575.740.3698--6.88--150.85------
Paul Hartmann AG2.12bn79.02m1.07bn11.03k13.481.216.960.505822.2522.25596.64248.811.452.685.68192,174.005.726.507.948.8157.5656.903.954.321.3350.780.014630.052.943.38-10.516.604.244.19
Fagron NV471.68m42.86m1.26bn2.49k29.106.0319.782.640.59480.58966.552.870.73883.8313.38189,581.606.782.348.894.1544.1644.789.184.110.66593.940.611338.418.806.60-8.130.5266-0.1623-30.06
Ypsomed Holding AG409.58m54.28m1.39bn1.60k25.444.0414.623.384.774.7736.0030.060.83415.324.82282,895.9011.059.9715.8713.8234.4731.2713.2510.940.672637.850.243628.63-2.6510.4315.5134.6133.3212.89
Medacta Group SA-90.26bn-90.26bn1.53bn973.00------------------------------------------------11.41--19.16------
Data as of Jun 25 2019. Currency figures normalised to Fagron NV's reporting currency: Euro EUR

Institutional shareholders

14.66%Per cent of shares held by top holders
HolderShares% Held
Evermore Global Advisors LLCas of 12 Apr 20192.20m3.07%
JPMorgan Asset Management (UK) Ltd.as of 11 Apr 20191.96m2.73%
Carmignac Gestion SAas of 12 Apr 20191.49m2.08%
The Vanguard Group, Inc.as of 31 May 20191.04m1.45%
Teslin Capital Management BVas of 30 Sep 2018884.06k1.23%
S.W. Mitchell Capital LLPas of 31 Mar 2019631.82k0.88%
KBC Asset Management NVas of 31 Dec 2018616.88k0.86%
BNP Paribas Asset Management Belgium SAas of 30 Apr 2019578.48k0.81%
Norges Bank Investment Managementas of 31 Dec 2018569.57k0.79%
BlackRock Fund Advisorsas of 06 Jun 2019553.07k0.77%
More ▼
Data from 31 Dec 2018 - 30 Apr 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.